New 'masked' cancer drug hides from healthy cells before killing tumours

New research into masked T-cell engagers cancer immunotherapies shows we can now "cloak" drugs to kill tumours safely.

Getting through a tough illness is a battle many of us or our loved ones face. While modern medicine is brilliant, some cancer treatments are so strong they accidentally attack the healthy parts of your body too.

But experts in Manchester have found a way to "mask" these powerful drugs. It is like giving a soldier a suit of invisible armour that only falls off when they are standing right in front of the enemy.

The superhero "speed bump"

The new drug, called VIR-5500, is what scientists call a "T-cell engager." Think of it as a microscopic piece of Velcro that grabs a cancer cell in one hand and an immune cell in the other.

By pulling them together, it forces your body's own immune system to blast the cancer with toxic chemicals. It is a highly effective way to clear out even the most stubborn tumours.

However, these drugs can sometimes be too "angry," causing a dangerous reaction called cytokine release syndrome. This is where the body’s inflammation goes into overdrive and can lead to organ failure.

The 82% success rate

In a recent trial for advanced prostate cancer, the results were nothing short of phenomenal. Among patients given the highest doses, 82% saw a reduction in their PSA levels—a key sign the cancer is retreating.

Even better, nearly half of those patients saw their tumours actually shrink. This included not just the main tumour, but also "metastatic" ones that had spread to other parts of the body.

A mask that only melts in tumours

To stop the drug from hurting healthy organs, researchers covered it in a special "mask." This mask stays on while the drug travels through your blood, keeping it inactive and safe.

Once it hits the tumour, specific molecules found only in cancer break the mask down. The drug then "unmasks" and starts its attack exactly where it is needed.

Professor Sheena Cruickshank said: "Masking creates an effective drug that may also be safer. Tumour-specific activation should restrict the anti-cancer response to within the tumour."

Fewer side effects, better results

The most exciting part is that patients on the highest doses mostly suffered only "mild" side effects. This suggests the mask is doing its job by keeping the "war" contained within the tumour sites.

"If further research proves that masking T-cell engagers creates safer, more effective drugs, then we can expand what we can do with them," the team noted. They could soon be combined with traditional treatments like chemo for an even bigger impact.

While the trials are still ongoing, this "cloak and dagger" approach offers huge hope for the future. It could soon be used to tackle everything from lung cancer to hepatitis B.

Related Links:

MORE: AI in Breast Cancer Screening Boosts Detection by 10% and Cuts Result Wait Times to Just 3 Days! — https://trendwiremedia.com/2026/03/15/ai-in-breast-cancer-screening-boosts-detection-by-10-and-cuts-result-wait-times-to-just-3-days/

MORE: Head and Neck Cancer Deaths 2.5 Times Higher in Deprived Areas of Northern England and Scotland — https://trendwiremedia.com/2026/03/11/head-and-neck-cancer-deaths-2-5-times-higher-in-deprived-areas-of-northern-england-and-scotland/

MORE: Google AI Outperforms Doctors in Largest NHS Breast Cancer Screening Study Across UK — https://trendwiremedia.com/2026/03/10/google-ai-outperforms-doctors-in-largest-nhs-breast-cancer-screening-study-across-uk/

OFFICIAL SOURCE VERIFICATION: This report is based on official data from University Newsroom. Document: Masked T‑cell engagers: cancer immunotherapies for the future? Source Link: https://www.manchester.ac.uk/about/news/masked-tcell-engagers-cancer-immunotherapies-for-the-future/